Search Results
Found 1 results
510(k) Data Aggregation
(136 days)
Degradable Solutions AG
easy-graft™ is indicated for the treatment of intraoral / maxillofacial osseous defects. Dental and maxillo-facial Indications may include:
- . Extraction defects (alveolar ridge preservation)
- Periodontal defects .
- Peri-implant defects .
- Augmentation of deficient alveolar crest (e.g. Guided Bone Regeneration, GBR) ・
- Sinus floor augmentation .
- Defects after surgical extractions -
- Defects after removal of bone cysts
- Defects after root resection or apicoectorny
- Defects after removal of autotogous bone .
easy-graft™ contains:
- Syringe containing beta-tricalcium phosphate (β-TCP) granules coated with poly(lactide-co-alvcolide) (PLGA)
- Ampule containing BioLinker™ (N-methyl-2-pyrrolidone and water) .
easy-graft™ is a bioresorbable, synthetic, porous bone graft substitute. It consists of two components: granules (supplied in a syringe) and BioLinker™ (supplied in an ampule). After mixing the components together, easy-graft" forms a moldable mass that can be applied directly from the syringe into the bone defect. easy-graft™ hardens in contact with body fluids, allowing a working time of approximately one minute after application into the bone defect. Depending on · blood inflow, hardening may take longer.
easy-graft™ is provided in the particle sizes of 500 – 630 µm for smaller defects and 500 – 1000 um for larger defects.
easy-graft™ is a biocompatible and osteoconductive material that allows for complete resorption by the body.
easy-graft™ can be used in combination with dental membranes.
easy-graft" contains no animal or human derived substances. β-TCP and PLGA are derived from synthetic raw materials.
This inquiry concerns a 510(k) Summary for the easy-graft™ bone grafting material, which focuses on device equivalence rather than diagnostic performance criteria or studies in the traditional sense of AI/CADe devices. Therefore, many of the requested categories (e.g., sample size for test set, number of experts for ground truth, adjudication methods, MRMC studies, standalone performance, training set details) are not applicable or cannot be extracted from this type of regulatory document.
However, based on the provided text, here's what can be gathered regarding the acceptance criteria and the study that proves the device meets them:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for easy-graft™ are primarily based on demonstrating substantial equivalence to predicate devices and adherence to relevant standards and guidance documents. The "reported device performance" in this context refers to the demonstration that easy-graft™ meets these equivalence criteria and is safe and effective for its intended use.
| Acceptance Criteria Category | Specific Criteria | Reported Device Performance (Summary) |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Substantial Equivalence | - Intended Use: Same as predicate devices (calc-i-oss, Cerasorb, Bio-Oss, FortOss Vital) for intraoral/maxillofacial osseous defects.
- Materials: Equivalent materials to predicate devices (β-TCP to calc-i-oss, Cerasorb; PLA polymers and N-methyl-2-pyrrolidone to Atrisorb, Inion Membrane).
- Form: Similar handling properties to predicate devices (CalMatrix, Fortoss Vital - moldable, implant, hardening in defect). Identical granule shape/size to calc-i-oss.
- Porosity: Porous, like predicate devices (calc-i-oss, Cerasorb, BioOss).
- Resorption/Bone Growth: Resorbs and replaced by bone during healing, like predicate devices (calc-i-oss, Cerasorb, FortOss Vital).
- Mode of Action: Displays the same osteoconductive mode of action as predicate bone graft substitute devices (calc-i-oss, Cerasorb). | The document explicitly states: "The results of the chemical and physical characterization, biocompatibility and performance testing / evaluations demonstrate substantial equivalence of easy-graft™ to the predicate devices in intended use, technological characteristics and performance." |
| Risk Mitigation (as per FDA Guidance) | - Ineffective Bone Formation: Addressed by physical characterization (FDA Guidance Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices), chemical composition testing (same guidance), animal testing, and labeling. - Adverse Tissue Reaction: Addressed by physical characterization, chemical composition testing (same guidance), biocompatibility in accordance with #G95-1 (FDA Blue Book Memorandum, ISO-10993), animal testing, and labeling.
- Infection: Addressed by sterilization according to ISO 11137 (SAL
Ask a specific question about this device
Page 1 of 1